Abstract:OBJECTIVE To evaluate the dosing regimens of levofloxacin. METHODS The drug concentrations in serum and urine were assayed by HPLC method and the pharmacokinetic parameters were calculated after intravenous infusion of a single dose of 200 mg, 300 mg and 500 mg levofloxacin to healthy volunteers. The in vitro activity MIC of levofloxacin against 823 clinical isolates were determined and compared with other antimicrobial agents. Based on the above results, the PK/PD parameters C(max)/MIC and AUC/MIC were calculated and the dosing regimens of levofloxacin were proposed for infections caused by different pathogens. RESULTS The results of clinical pharmacokinetic study showed that the C(max) of levofloxacin was 3.4 mg/L +/- 0.8 mg/L, 4.8 mg/L +/- 1.4 mg/L and 7.6 mg/L +/- 1.1 mg/L respectively, AUC(0-infinity) was 14.4 mg.h/L +/- 2.5 mg.h/L, 21.9 mg.h/L +/- 4.5 mg.h/L and 38.3 mg.h/L +/- 4.9 mg.h/L respectively, T(1)/2 beta was 6.2 h +/- 0.4 h, 6.4 h +/- 0.9 h and 6.5 h +/- 0.6 h respectively, and 69% +/- 5%, 69% +/- 6%, and 65% +/- 4% of the doses were excreted in urine within 24 h after intravenous infusion of a single dose of levofloxacin 200 mg, 300 mg and 500 mg. The in vitro pharmacodynamic study showed that levofloxacin was highly active against Hemolytic streptococcus and Moraxella catarrhalis. It was active against Streptococcus pneumoniae (including penicillin nonsusceptible strains), Hemophilus influenzae, methicillin-sensitive Staphylococcus aureus (MSSA), Klebsiella pneumoniae and Stenotrophomonas maltophilia. Levofloxacin also had good activity against Pseudomonas aeruginosa and K.pneumoniae. However, most of isolates of enterococcal spp. were resistant to levofloxacin. Above 50% of Escherichia coli isolates were resistant to levofloxacin. Based on the results of PK/PD parameters, the adequate dosing regimens of levofloxacin should be once daily 200 mg once daily of levofloxacin was expected to be effective for the treatment of infections caused by M. catarrhalis. The regimen of 300 mg once daily could be effective for the treatment of infections caused by Hemolytic streptococcus. 500 mg once daily of levofloxacin was expected to be effective for the treatment of respiratory tract infections caused by S. pneumoniae or H. influenzae. For treatment of respiratory tract infections and urinary tract infections caused by levofloxacin-susceptible organisms including K. pneumoniae, E. coli, P. aeruginosa, and S.maltophilia, 500 mg once daily of levofloxacin was needed to obtain good clinical efficacy. But PK/PD parameters predicted that 500 mg daily of levofloxacin was not effective for infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and Enterococci. CONCLUSION The proposed dosing regimens of levofloxacin based on PK/PD concepts are expected to provide good efficacy in clinical practice.

Analysis of 37 Cases on Allergic shock Induced by Levofloxacin

Adverse Drug Reactions Induced by Gatifloxacin:Analysis of 866 Cases During 2003～2006

[Adverse Drug Reaction and Rational Use of Levofloxacin: a Prospective Study].

Association Between the Rate of Fluoroquinolones-Resistant Gram-Negative Bacteria and Antibiotic Consumption from China Based on 145 Tertiary Hospitals Data in 2014

Meta-analysis of High-dose and Routine-dose of Levofloxacin in the Treatment of Respiratory Tract Infection

A retrospective study of the efficacy and safety of levofloxacin in children with severe infection

A randomized multicenter clinical study of injectable levofloxacin in the treatment of acute bacterial infections

Clinical Study on High Dosage Levofloxacin Veno-Preparation for the Treatment of Respiratory Tract Infections

Clinical evaluation of pazufloxacin and levofloxacin in the treatment of bacterial infections

Analysis of 114 Severe ADR Cases Induced by Antibacterial Drugs in Our Hospital

Safety Profile of Fluoroquinolones: Analysis of Adverse Drug Reactions in Relation to Consumption Data Using Pharmacovigilance Database in Hebei, China

Acute pancreatitis associated with the antibiotic levofloxacin: A rare case report

Pharmacokinetics of single 500-milligram doses of intravenous levofloxacin in middle-age healthy volunteers

[Study of Pharmacokinetics/pharmacodynamics of Levofloxacin].

Analysis of the Adverse Drug Reactions Reports of 139 Cases

Analysis on 522 cases of antibacterial-related adverse drug reaction/event reports

Drug-induced immune haemolytic anaemia caused by levofloxacin

Clinical analysis of severe adverse drug reactions in Peking Union Hospital from 2013 to 2015

In-vitro activity of levofloxacin against bacterial pathogens collected in China：A ten-year（2009-2018） retrospective study

A Rare Case of Levofloxacin-Induced Acute Pancreatitis: Case Report and Literature Review

Analysis of Safety Difference of 10 Kinds of Commonly Used Anti-Infective Agents with Same Generic Drugs Name Based on the Adverse Drug Reaction Data